Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Acorda Therapeutics, Inc.
Type
Public
Traded as NASDAQ: ACOR
S&P 600 Component
FWB: CDG
Industry Health care
Biotechnology
Founded 1995 (1995)
Founder Ron Cohen
Headquarters Ardsley, New York, United States
Key people
Ron Cohen (CEO)
Andrew R. Blight
Products Zanaflex
Ampyra
Qutenza
Revenue Increase US$292.2 Million (FY 2011)
Operating income
Increase US$35.1 Million (FY 2011)
Net income
Increase US$30.6 Million (FY 2011)
Total assets Increase US$379.5 Million (FY 2011)
Total equity Increase US$205.2 Million (FY 2011)
Number of employees
328 (February, 2012)
Website Acorda.com

Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.

In September 2014 the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.

In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.

In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.

As of November 5, 2017, the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, Ian F. Smith, and Catherine Strader.

Investment goal date:
Dividends reinvested
Acorda Therapeutics, Inc. ACOR report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-28
--
--
Q4 2017
2018-02-12
--
--
Q3 2017
2017-10-31
0.4300
-0.5500
Q2 2017
2017-07-27
0.2900
-0.1800
Q1 2017
2017-04-27
-0.0800
-0.4100
Q4 2016
2017-02-14
0.0500
-0.0700
Q3 2016
2016-10-27
-0.0400
-0.2800
Q2 2016
2016-07-28
0.0700
-0.4000
Q1 2016
2016-04-28
0.0700
-0.0100
Q4 2015
2016-02-11
0.2800
0.2100
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BAKER BROS. ADVISORS LP
3301791
Bank of New York Mellon Corp
582298
BlackRock Fund Advisors
4310090
BlackRock Inc.
6425256
BlackRock Institutional Trust Company, N.A.
1248655
CAMBIAR INVESTORS LLC
835643
Clearbridge Investments, LLC
945338
Consonance Capital Management LP
619419
DIMENSIONAL FUND ADVISORS LP
1831450
FMR LLC
6650018
PRICE T ROWE ASSOCIATES INC /MD/
590040
SCOPIA FUND MANAGEMENT, LLC
5568306
Sio Capital Management, LLC
1045400
STATE STREET CORP
1624743
Vanguard Group, Inc
4139589
Major Shareholders
Name Relationship
Total Shares
Holding stocks
BLANK BURKHARD
0.1100% (44200)
ACOR /
PANEM SANDRA PHD
0.0100% (2912)
ACOR /
ROGERS MICHAEL W
0.1000% (40713)
LAWRENCE DAVID
0.0200% (8686)
ACOR /
COHEN RON
1.2300% (511648)
ACOR / DYAX /
SCOPIA FUND MANAGEMENT, LLC
20.3000% (8474728)
ACOR / ITRI / PHH /
Blight Andrew
0.1900% (78594)
ACOR /
Wasman Jane
0.2600% (106674)
ACOR /
Sabella Lauren M
0.0400% (16349)
ACOR /
Wessel Thomas
0.0900% (36350)
ACOR /
Carrazana Enrique J.
0.0800% (32148)
ACOR / MRNS /
Hindman Andrew A.
0.1100% (46123)
ACOR /
% ()